CN102786682B - Polyethylene glycol aldehyde group active substance - Google Patents
Polyethylene glycol aldehyde group active substance Download PDFInfo
- Publication number
- CN102786682B CN102786682B CN201110131355.0A CN201110131355A CN102786682B CN 102786682 B CN102786682 B CN 102786682B CN 201110131355 A CN201110131355 A CN 201110131355A CN 102786682 B CN102786682 B CN 102786682B
- Authority
- CN
- China
- Prior art keywords
- polyoxyethylene glycol
- residue
- aldehyde radical
- amino
- actives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCOC(C(NCC*)=O)OCC Chemical compound CCOC(C(NCC*)=O)OCC 0.000 description 1
Abstract
The invention discloses a polyethylene glycol aldehyde group active substance which has a structural general formula shown in the description, wherein P is a polyethylene glycol residue; Z is selected from an alkyl or amido substituted alkyl residue or amido residue, or is zero; F is selected from an alkyl of CbHc; t is an integer. The polyethylene glycol aldehyde group active substance of the invention has the characteristics of simple preparation, strong generality, and the like, and has wide application value.
Description
Technical field
The present invention relates to a kind of polyethylene active thing, particularly relate to the novel polyoxyethylene glycol aldehyde radical actives of a class.
Background technology
Polyoxyethylene glycol (PEG) is a kind of macromolecular material, and it does not almost have toxic side effect to human body.Pegylation technology is by the polyethyleneglycol derivative with active group and protein medicaments Chemical bond, can effectively extend the proteic substance circulation residence time in vivo, causes medicine blood plasma cycle stretch-out and improves curative effect.In addition Pegylation can modifying protein surface, changes immunogenicity, thereby reaches the object that reduces immune untoward reaction.
Polyethylene active thing is widely used at a lot of business medicines as the carrier of preparing medicine, and order state FDA has ratified the medicine of Pegylation in 10, relates to the PEG modification of the medicines such as enzyme, albumen, polypeptide, somatomedin.Wherein
be the product after a kind of somatomedin and polyoxyethylene glycol aldehyde radical active phase connect, shown better result for the treatment of and longer body-internal-circulation transformation period.
Polyoxyethylene glycol can also be applied to new type medical equipment aspect, and especially in surface modification, improving biocompatibility in body has very large advantage, at the new type medical equipment of American-European listing recent years, has all applied polyethylene active thing.Polyoxyethylene glycol can also be linking agent, should prepare pharmaceutical gel, as tackiness agent, medicament slow release gel, hemostatic material etc.
Early stage drug modified aspect, is all the polyethylene active thing that uses straight chain, and the use of multi-arm polyethylene glycol actives in recent years starts to increase.
But in the preparation of conventional polyoxyethylene glycol aldehyde radical actives, also has certain difficulty at present, although US5990237A has reported the synthetic of a kind of straight chain polyoxyethylene glycol propionic aldehyde actives, but its transformation efficiency is not high, utilize the synthetic multi-arm polyethylene glycol actives aldehyde radical side of the method more difficult.
Summary of the invention
The technical problem to be solved in the present invention is to provide the novel polyoxyethylene glycol aldehyde radical actives of a class.It is simple that such aldehyde radical actives has preparation, the feature of highly versatile.
For solving the problems of the technologies described above, polyoxyethylene glycol aldehyde radical actives of the present invention, has following structure:
Wherein, P is various polyethylene glycols residues, and Z and F are spacer group, and wherein, Z can be selected from: alkyl, amino alkyl residue, the amino residue replacing or be zero (not existing); T is the aldehyde radical number in actives, and t is integer, and scope is: 1≤t≤16; Be preferably 1≤t≤8, more preferably 1≤t≤6, are especially preferably 1≤t≤4.
F in general formula I is selected from: C
bh
calkyl; Wherein, b, c are integer: 0≤b≤20,0≤c≤40; Be preferably 0≤b≤15,0≤c≤30; More preferably 0≤b≤10,0≤c≤20; Especially be preferably 0≤b≤8,0≤c≤16.
P in general formula I comprises: the polyoxyethylene glycol residue of linear chain structure; The polyoxyethylene glycol residue of multi-arm structure; The product residue that carboxylated straight chain polyoxyethylene glycol and the amino-acid residue with polyamino are connected; Wherein, in the polyoxyethylene glycol residue of the polyoxyethylene glycol of linear chain structure and multi-arm structure, have at least the residue of a hydroxyl and Z to be connected: carboxylated straight chain polyoxyethylene glycol and the amino-acid residue with polyamino, this residue is connected with Z by the carboxyl on amino acid.
Wherein, the polyethylene glycols residue of linear chain structure, comprising:
The polyoxyethylene glycol of corresponding these linear chain structure, can adopt commerical prod or can be obtained by simple aggregation, conventionally uses oxyethane, with the method acquisition of ionic polymerization.
The polyethylene glycols residue of multi-arm structure, comprising:
(1) 3 arm polyethylene glycols residue, comprising:
(2) 4 arm polyethylene glycols residues, comprising:
(3) 6 arm polyethylene glycols residues, comprising:
(4) 8 arm polyethylene glycols residues, comprising:
(5) Y type 2 arm polyethylene glycols residues, comprising:
The polyoxyethylene glycol of corresponding these multi-arm structures, can adopt commerical prod, or take polyvalent alcohol as initiator, can be obtained by simple aggregation, conventionally uses oxyethane, with the method acquisition of ionic polymerization.
As a general scheme, the P described in the present invention is not confined to above-mentioned polyoxyethylene glycol residue, and it can be also the product residue that multiple straight chain polyoxyethylene glycol and the amino-acid residue with polyamino are connected, and structure comprises:
Wherein, L is the abbreviation with the amino-acid residue of polyamino, and its general formula is II,
C
vH
wO
uN
y II
V, w, u, y are all integer, 3≤v≤10,6≤w≤20,2≤u≤6,2≤y≤6; Preferably 4≤v≤8,8≤v≤16,2≤y≤4,2≤u≤4; Especially preferably L is lysine residue, and structure is as follows:
But commonly 2 carboxylated straight chain polyoxyethylene glycol and the structure that has two amino amino-acid residues and be connected, be connected it with diamine, obtains a new Y type polyoxamide, and this Y type polyoxamide also can adopt commerical prod.Modal such polyoxamide is to be connected by 2 straight chain polyoxyethylene glycol and lysine residue, then with the quadrol gained that is connected, structure illustrates as follows:
X in P-structure in general formula I of the present invention is number of repeat unit, is also the polymerization degree, and x is integer, 20≤x≤4000; Be preferably 20≤x≤3000; Be more preferably 20≤x≤2000; Especially be preferably 40≤x≤2000.
In the time of the polyoxyethylene glycol residue of the P polyoxyethylene glycol that is linear chain structure or multi-arm structure, Z is C
dh
ealkyl or do not exist, wherein, 1≤d≤10,2≤e≤20; Be preferably 1≤d≤8,2≤e≤16; Be more preferably 1≤d≤6,1≤e≤12; Especially be preferably 1≤d≤4,2≤e≤8;
In the time of the P product residue that to be carboxylated straight chain polyoxyethylene glycol be connected with the amino-acid residue with polyamino, Z is the residue of the amino alkyl replacing or is exactly amino residue, amino on Z is connected with the carboxyl residue of L, Z structure as described in general formula III, wherein, i and h are integer, 0≤i≤10,0≤h≤20, preferably 0≤i≤6,0≤h≤12.
HN——C
iH
h III
For preparation said structure polyoxyethylene glycol aldehyde radical actives of the present invention; when concrete enforcement; usually can adopt commercial polyoxyethylene glycol-alkylamino substituent (again referred to as polyoxamide) that can obtain; carboxylic acid with aldehyde radical protection; under the effect of condensing agent, there is condensation reaction, obtain the protected polyethylene active thing of aldehyde radical, then remove the blocking group of aldehyde radical; obtain target product, take product as straight chain dialdehyde base priming reaction equation schematically as follows:
As adopt the polyoxamide of four arm configurations, structure is as follows:
Can obtain following product:
Because the guard method of aldehyde radical is varied; so the carboxylic acid of aldehyde radical protection is not to only have the acetal protection of above formula a kind of in the present invention; any whenever possible after generation condensation reaction; through deprotection, then the method that obtains the aldehyde radical polyethylene active thing shown in general formula I is all applicable to the present invention.
It should be noted that: because polymer is mutually mixed in together, can not effectively separate, so can not obtain pure polyethylene active thing, polyoxyethylene glycol aldehyde radical actives is no exception.Take 4 arm polyoxamides as example, conventionally by 4 arm polyoxyethylene glycol, through amino-alkylation, reaction obtains, but the transformation efficiency that can not guarantee amino-alkylation reaction is 100%, it is actual that what obtain is a mixture, 1,2,3,4 substitution products and unreacted 4 arm polyoxyethylene glycol are comprised, therefore, in routine duties, can weigh by aldehyde end group replacement rate the quality of product.
Same reason, can not obtain pure 4 arm polyoxyethylene glycol aldehyde radical activess, and only getable be a mixture, comprised 1,2,3,4 substitution products and unreacted 4 arm polyoxamides.Even the methoxy poly (ethylene glycol) aldehyde radical actives for following structure:
Also must obtain the mixture that has comprised methoxy poly (ethylene glycol) amine.
A PEGlike coating aldehyde radical actives of the present invention, the polyethylene glycol structures that comprises straight chain and various multi-arms, therefore, the invention provides the versatility scheme of the polytype polyoxyethylene glycol aldehyde radical actives of preparation, and polyoxyethylene glycol aldehyde radical actives preparation method of the present invention is simple, highly versatile.
The purposes of polyoxyethylene glycol aldehyde radical actives of the present invention is very extensive, as can be used as the modification of bio-active substance, for the Improvement of material, medicine and other fields, provides foundation.As polyoxyethylene glycol aldehyde radical actives of the present invention can be for modifications such as protein, polypeptide, enzyme, somatomedins, by being connected and reaching the object of modification with the terminal amino group of these bio-active substances, as polyoxyethylene glycol aldehyde radical actives can be under acidic conditions, be connected with the amino selectivity of the end of protein matter, concrete grammar can referenced patent: US 5985265A.
Embodiment
Embodiment 1
The methoxy poly (ethylene glycol) amine (5g, molecular weight is 5000) of 0.001mol, puts into the round-bottomed flask of 250ml in the lump with 100ml toluene, heats up toluene distillation to go out, and removes moisture.Add the anhydrous methylene chloride of 100ml, making material dissolution complete, then adding dry 9,9-diethoxy n-nonanoic acid 0.0012mol, adding condensing agent carbonyl dimidazoles 0.0015mol, after 0-5 ℃ of reaction 12h, the insoluble object of elimination, by extremely about 15ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 150ml, can obtain white solid product, then drying treatment, obtain final product 4.1g, productive rate 82%.
Embodiment 2
Gained 4.1g product in embodiment 1 is dissolved in the phosphate aqueous solution of 4mol/L of 40ml, at 0-5 ℃, stir 10h, divide 3 extractions with 300ml methylene dichloride, by extremely about 15ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 150ml, can obtain white solid product, then drying treatment, obtain final product 3.6g, productive rate 87%.
NMR (CDCl
3) δ: 3.50 (wide unimodal, the hydrogen in PEG), CH
3o-and-CH
2nHCO-, 3.31～3.40, one unimodal and one three split peak, 5H;-CH
2cH
2nHCO-, 1.72～1.82, five split peak, 2H;-NHCO-, 6.22～6.33, unimodal, 1H;-CH
2cONH-, 2.10～2.17, three split peak, 2H;-CH
2cHO, 2.38～2.45, three split peak, 2H;-CH
2cH
2cHO and-CH
2cH
2cONH-, 1.55～1.68, wide unimodal, 4H; Near its excess-three in aldehyde molecule segment-CH
2-, 1.24～1.38, wide unimodal, 6H;-CHO, 9.74～9.77, unimodal, 1H.On nuclear-magnetism, judge that aldehyde end group replacement rate is greater than 95%.
Embodiment 3
The 4 arm polyoxamides (20g, molecular weight is 20000) of 0.001mol, put into the round-bottomed flask of 500ml in the lump with 200ml toluene, heat up toluene distillation to go out, and remove moisture.Add the anhydrous methylene chloride of 200ml, making material dissolution complete, then adding dry 2,2-diethoxy acetic acid acid 0.0012mol, adding condensing agent carbonyl dimidazoles 0.0015mol, after 0-5 ℃ of reaction 12h, the insoluble object of elimination, by extremely about 45ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 300ml, can obtain white solid product, then drying treatment, obtain final product 17g, productive rate 85%.
Embodiment 4
Embodiment 3 gained 17g products are dissolved in the phosphate aqueous solution of 4mol/L of 120ml, at 0-5 ℃, stir 10h, divide 3 extractions with 600ml methylene dichloride, by extremely about 35ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 300ml, can obtain white solid product, then drying treatment, obtain final product 16g, productive rate 94%.
NMR (CDCl
3) δ: 3.50 (wide unimodal, the hydrogen in PEG), C-(CH
2o)
4-and-CH
2nHCO-, 3.31～3.45, one unimodal and one three split peak ,-CHO, 9.74～9.77, unimodal, 1H.On nuclear-magnetism, judge that aldehyde end group replacement rate is greater than 95%.
Embodiment 5
The Y type polyoxamide (10g, molecular weight is 10000) of 0.001mol, structure is as follows:
Put in the lump the round-bottomed flask of 250ml with 100ml toluene, heat up toluene distillation to go out, remove moisture.Add the anhydrous methylene chloride of 100ml, making material dissolution complete, then adding dry 9,9-diethoxy n-nonanoic acid 0.0012mol, adding condensing agent carbonyl dimidazoles 0.0015mol, after 0-5 ℃ of reaction 12h, the insoluble object of elimination, by extremely about 30ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 250ml, can obtain white solid product, then drying treatment, obtain final product 8.6g, productive rate 86%.
Reaction formula is as follows:
Embodiment 6
Embodiment 5 gained 8.6g products are dissolved in the phosphate aqueous solution of 4mol/L of 80ml, at 0-5 ℃, stir 10h, divide 3 extractions with 800ml methylene dichloride, by extremely about 35ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 300ml, can obtain white solid product, then drying treatment, obtain final product 8.1g, productive rate 94%.
NMR (CDCl
3) δ: 3.50 (wide unimodal, the hydrogen in PEG and acid amides side CH
2on 2H), C-(CH
2o)
4-and-CH
2nHCO-, 3.31～3.45, one unimodal and one three split peak ,-CHO, 9.74～9.77, unimodal, 1H;-CH
2-CH
2-(amino acid), triplet, 1.56,4H; 6.02, triplet, 1H; 2.9～3.1, amino connected CH
2, 6H.On nuclear-magnetism, judge that aldehyde end group replacement rate is greater than 92%.
Embodiment 7
The Y type polyoxamide (60g, molecular weight is 60000) of 0.001mol, structure is as follows:
Put in the lump the round-bottomed flask of 1000ml with 600ml toluene, heat up toluene distillation to go out, remove moisture.Add the anhydrous methylene chloride of 500ml, making material dissolution complete, then adding dry 9,9-diethoxy n-nonanoic acid 0.0012mol, adding condensing agent carbonyl dimidazoles 0.0015mol, after 0-5 ℃ of reaction 12h, the insoluble object of elimination, by extremely about 200ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 2500ml, can obtain white solid product, then drying treatment, obtain final product 54g, productive rate 90%.
Reaction formula is as follows:
Embodiment 8
Embodiment 7 gained 54g products are dissolved in the phosphate aqueous solution of 4mol/L of 500ml, at 0-5 ℃, stir 10h, divide 3 extractions with 4000ml methylene dichloride, by extremely about 250ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 3000ml, can obtain white solid product, then drying treatment, obtain final product 51g, productive rate 94%.
NMR (CDCl
3) δ: 3.50 (wide unimodal, the hydrogen in PEG), C-(CH
2o)
4-and the CH on aldehyde radical side
2, 3.2～3.45, multiplet, 5H;-CHO, 9.74～9.77, unimodal, 1H; CH
2, 2.9, quartet, 2H; CH
2, 1.7, triplet, 2H; .On nuclear-magnetism, judge that aldehyde end group replacement rate is greater than 94%.
Embodiment 9
The methoxy poly (ethylene glycol) amine (2g, molecular weight is 2000) of 0.001mol, structure is as follows:
Put in the lump the round-bottomed flask of 100ml with 200ml toluene, heat up toluene distillation to go out, remove moisture.Add the anhydrous methylene chloride of 50ml, making material dissolution complete, then adding dry 9,9-diethoxy n-nonanoic acid 0.0012mol, adding condensing agent carbonyl dimidazoles 0.0015mol, after 0-5 ℃ of reaction 12h, the insoluble object of elimination, by extremely about 15ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 200ml, can obtain white solid product, then drying treatment, obtain final product 1.64g, productive rate 82%.
Reaction formula is as follows:
Embodiment 10
Embodiment 9 gained 1.64g products are dissolved in the phosphate aqueous solution of 4mol/L of 20ml, at 0-5 ℃, stir 10h, divide 3 extractions with 200ml methylene dichloride, by extremely about 15ml of filtrate concentrated by rotary evaporation, concentrated solution is poured in the Virahol of 150ml, can obtain white solid product, then drying treatment, obtain final product 1.4g, productive rate 85%.
NMR (CDCl
3) δ: 3.50 (wide unimodal, the hydrogen in PEG), CH
3-(OCH
2cH
2)
4-and the CH2 on aldehyde radical side, 3.2～3.45, multiplet, 5H;-CHO, 9.74～9.77, unimodal, 1H; CH
2, 2.9, quartet, 2H; CH
2, 1.7, triplet, 2H; .On nuclear-magnetism, judge that aldehyde end group replacement rate is greater than 95%.
Claims (14)
1. the polyoxyethylene glycol aldehyde radical actives of a general formula I:
Wherein, P is polyethylene glycols residue;
Z is selected from: alkyl, amino alkyl residue, the amino residue replacing or do not exist;
F is selected from: C
bh
calkyl; Wherein, 0≤b≤20,0≤c≤40;
T is integer, and the scope of t is: 1≤t≤16.
2. polyoxyethylene glycol aldehyde radical actives as claimed in claim 1, is characterized in that: described P comprises: the polyoxyethylene glycol residue of linear chain structure; The polyoxyethylene glycol residue of multi-arm structure; The product residue that carboxylated straight chain polyoxyethylene glycol and the amino-acid residue with polyamino are connected;
Wherein, in the polyoxyethylene glycol residue of the polyoxyethylene glycol of linear chain structure and multi-arm structure, have at least the residue of a hydroxyl and Z to be connected: carboxylated straight chain polyoxyethylene glycol and the amino-acid residue with polyamino, be connected with Z by the carboxyl on amino acid.
3. as the polyoxyethylene glycol aldehyde radical actives in claims 2, it is characterized in that: the scope of described t is: 1≤t≤8;
0≤b≤15，0≤c≤30。
4. the polyoxyethylene glycol aldehyde radical actives as in claims 3, is characterized in that: the scope of described t is: 1≤t≤6;
0≤b≤10，0≤c≤20。
5. the polyoxyethylene glycol aldehyde radical actives as in claims 4, is characterized in that: the scope of described t is: 1≤t≤4;
0≤b≤8，0≤c≤16。
6. polyoxyethylene glycol aldehyde radical actives as claimed in claim 2, is characterized in that: the polyethylene glycols residue of described linear chain structure, comprising:
The polyethylene glycols residue of multi-arm structure, comprising:
Carboxylated straight chain polyoxyethylene glycol and the product residue that the amino-acid residue with polyamino is connected, comprising:
Above-mentioned x is integer, 20≤x≤4000;
L is the abbreviation with the amino-acid residue of polyamino, and its general formula is II,
C
vH
wO
uN
y II
V, w, u, y are all integer, 3≤v≤10,6≤w≤20,2≤u≤6,2≤y≤6.
7. polyoxyethylene glycol aldehyde radical actives as claimed in claim 6, is characterized in that: described 20≤x≤3000; 4≤v≤8,8≤v≤16,2≤u≤4,2≤y≤4.
8. polyoxyethylene glycol aldehyde radical actives as claimed in claim 7, is characterized in that: described 20≤x≤2000.
9. polyoxyethylene glycol aldehyde radical actives as claimed in claim 8, is characterized in that: described 40≤x≤2000.
10. polyoxyethylene glycol aldehyde radical actives as claimed in claim 7, is characterized in that: described L is lysine residue, and structure is as follows:
11. polyoxyethylene glycol aldehyde radical activess as claimed in claim 6, is characterized in that: when the polyoxyethylene glycol residue of the polyoxyethylene glycol that described P is linear chain structure or multi-arm structure, Z is C
dh
ealkyl or do not exist, wherein, 1≤d≤10,2≤e≤20;
In the time of the P product residue that to be carboxylated straight chain polyoxyethylene glycol be connected with the amino-acid residue with polyamino, Z is the residue of the amino alkyl replacing or is exactly amino residue, amino on Z is connected with the carboxyl residue of L, Z structure as described in general formula III, wherein, i and h are integer, 0≤i≤10,0≤h≤20;
HN——C
iH
h III。
12. polyoxyethylene glycol aldehyde radical activess as claimed in claim 11, is characterized in that: described 1≤d≤8,2≤e≤16; 0≤i≤6,0≤h≤12.
13. polyoxyethylene glycol aldehyde radical activess as claimed in claim 12, is characterized in that: described 1≤d≤6,2≤e≤12.
14. polyoxyethylene glycol aldehyde radical activess as claimed in claim 13, is characterized in that: described 1≤d≤4,2≤e≤8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110131355.0A CN102786682B (en) | 2011-05-20 | 2011-05-20 | Polyethylene glycol aldehyde group active substance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110131355.0A CN102786682B (en) | 2011-05-20 | 2011-05-20 | Polyethylene glycol aldehyde group active substance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102786682A CN102786682A (en) | 2012-11-21 |
| CN102786682B true CN102786682B (en) | 2014-05-21 |
Family
ID=47152282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110131355.0A Active CN102786682B (en) | 2011-05-20 | 2011-05-20 | Polyethylene glycol aldehyde group active substance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102786682B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960498B2 (en) * | 2006-06-30 | 2011-06-14 | Actamax Surgical Materials, Llc | Tissue adhesives with modified elasticity |
| CN101176791B (en) * | 2006-11-07 | 2013-01-09 | 中国药科大学 | Amino acid communicating with polyglycol as well as manufacturing method and usage thereof |
| EP2411062B1 (en) * | 2009-03-27 | 2014-08-20 | Actamax Surgical Materials LLC | Tissue adhesive and sealant comprising polyglycerol aldehyde |
| CN102108119A (en) * | 2009-12-25 | 2011-06-29 | 天津键凯科技有限公司 | Multi-arm polyethylene glycol derivative, combination thereof with medicine, and gel |
-
2011
- 2011-05-20 CN CN201110131355.0A patent/CN102786682B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102786682A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5544357B2 (en) | Polymer conjugate of a physiologically active substance having a hydroxyl group | |
| DK2806896T3 (en) | Chitosan covalently bound to small molecule integrin antagonist for targeted delivery | |
| EA016911B1 (en) | Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof | |
| WO2009142326A1 (en) | Docetaxel polymer derivative, method for producing same and use of same | |
| JP2013520986A5 (en) | ||
| CN101190891B (en) | Dihydrazide compound and its preparation method and application | |
| CN104479126B (en) | Multi-arm polyethylene glycol stearic acic derivative and oleic acid derivatives | |
| CN102408445A (en) | Hexaminoacid ester phenoxyl cyclotriphosphazene, its fluorescent nano-microsphere and preparation method thereof | |
| CN104356196A (en) | Oligopeptide based reductive sensitive lipid derivative and application of derivative in drug delivery | |
| JP4314229B2 (en) | Amphiphilic cyclic phosphazene trimer having temperature sensitivity and biocompatibility and method for producing the same | |
| JP2014507398A (en) | Hydrophobic drug formulation by micelle encapsulation using amphiphilic cyclic phosphazene trimer and method for producing the same | |
| WO2016167333A1 (en) | Polyion complex of poly(l-arginine) segment-containing block copolymer and polyanionic polymer | |
| CN102786682B (en) | Polyethylene glycol aldehyde group active substance | |
| KR101850424B1 (en) | Posphazene-based polymer for tissue adhesion, a method for preparing the same and use thereof | |
| CN103159959A (en) | M-PLGA-TPGS star type amphiphilic copolymer and preparation method and application | |
| WO2018038166A1 (en) | Polymer, method for producing polymer, and drug complex | |
| TW201737946A (en) | Drug-conjugated block copolymer, block copolymer, and method for producing drug-conjugated block copolymer | |
| CN112716887B (en) | Bioactive antioxidant polysalicylic acid hydrogel and preparation method and application thereof | |
| CN105111240B (en) | Nano microsphere DOPO-HQ ring three phosphazene derivative and preparation method thereof | |
| CN101507833B (en) | Injectable in-situ gel preparation method using poly aspartic acid derivate | |
| CN107303393B (en) | The preparation and application of Propofol polyethylene glycol conjugation prodrug | |
| US20170079928A1 (en) | Copolymers of formula (i) and uses | |
| CN1206257C (en) | Hydrophilic polymer-combo of silybum mariamum extract product as well as medicinal combination containing the combo | |
| KR20170016822A (en) | Novel polymer-based hydrotropes for hydrophobic drug delivery | |
| CN103360609A (en) | Novel amphiphilic protein-high molecule bonding body and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Fan Jun Inventor after: Wang Guowei Inventor after: You Kai Inventor before: Fan Jun |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FAN JUN TO: FAN JUN WANG GUOWEI YOU KAI |
|
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI SEEBIO BIOTECH, INC. Free format text: FORMER OWNER: SHANGHAI JINGYU BIO-TECHNOLOGY CO., LTD. Effective date: 20150602 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201609 SONGJIANG, SHANGHAI TO: 201204 PUDONG NEW AREA, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150602 Address after: Bi Sheng Road 201204 Shanghai Zhangjiang hi tech Park 299 Lane 11, Room 502 Patentee after: Shanghai Seebio Biotech Inc. Address before: Songjiang District Yexie town 201609 Shanghai Sheng Road No. 8 Patentee before: SHANGHAI JINGYU BIOTECHNOLOGY CO., LTD. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Bi Sheng Road 201204 Shanghai Zhangjiang hi tech Park 299 Lane 11, Room 502 Patentee after: West Bao biological technology (Shanghai) Limited by Share Ltd Address before: Bi Sheng Road 201204 Shanghai Zhangjiang hi tech Park 299 Lane 11, Room 502 Patentee before: Shanghai Seebio Biotech Inc. |